Azitra Presents Preclinical Data From ATR-04 At Society Of Investigative Dermatology Annual Meeting
Azitra Presents Preclinical Data From ATR-04 At Society Of Investigative Dermatology Annual Meeting
Azitra 在皮膚病學研究學會年會上公佈來自 ATR-04 的臨床前數據
- ATR-04 is in development for epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approximately 150,000 patients in the US
- Reduces methicillin-resistant S. aureus by 99% on ex vivo pig skin
- Reduces IL-36g, a pro-inflammatory cytokine that drives inflammation in EGFRi-induced toxicity, in human skin model by 75% compared to erlotinib-treated skin
- Increases human beta defensin 18-fold vs. vehicle on human skin model
- ATR-04 正在開發用於表皮生長因子受體抑制劑 (eGFRI) 誘發的皮膚毒性，該毒性影響了美國大約 150,000 名患者
- 減少對甲氧西林的耐藥性 金黃色葡萄球菌 開啓率提高了99％ 活體外 豬皮
- 與接受厄洛替尼治療的皮膚相比，在人體皮膚模型中，IL-36g（一種促炎細胞因子，可在 EGFRI 誘發的毒性中引起炎症）降低 75%
- 與人體皮膚模型上的載具相比，人體 β 防禦素提高了 18 倍
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。